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INTRODUCTION 
          Thyroid neoplasms constitute the most commonly occurring 
endocrine tumors worldwide, the majority of which are well 
differentiated cancer representing upto 90% of thyroid cancer having 
favorable clinical course. The group of poorly differentiated and 
undifferentiated thyroid cancer have a poor outcome and need a strict 
clinical surveillance. Malignant tumors of thyroid are prevalent 
worldwide. A survey conducted by WHO during 2010 revealed that 
around 44,670 new cases had appeared of which 1690 deaths occurred 
due to thyroid malignancy. 
 The main purpose of this study is to determine the role of beta-
catenin in well differentiated and poorly differentiated / undifferentiated 
carcinomas. Beta-catenin is a part of  membrane bound cell growth 
signaling complex that plays a role in cell adhesion, as well as promotion 
of growth through activation of wnt signaling pathways. Oncogenic 
signaling may result in release of this beta- catenin to accumulate in 
cytoplasm and translocate into the nucleus there by promoting the 
transcription genes (bcl-1 and c-myc) to induce cell proliferation.  
Hence abnormal expression of these  molecule in various thyroid tumors 
may be helpful in predicting the outcome of the disease. 
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AIM : 
 To study the immunohistochemical expression of beta catenin in 
thyroid tumors and thereby comparing its expression in well 
differentiated and  poorly differentiated / undifferentiated carcinomas. 
Objectives  : 
1. To study the expression of beta catenin in different thyroid tumors. 
2. To study the value of beta catenin in differentiating well 
 differentiated and poorly differentiated / undifferentiated 
 carcinomas. 
3. To identify tumors which may  not have favorable outcome. 
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THYROID GLAND 
DEVELOPMENT  
 The thyroid gland develops from the thyroid diverticulum in the 
midline of the floor of the foregut. The thyroid diverticulum migrates 
caudually to its adult anatomic position, but remains attached to the 
foregut by thyroglossal duct which is later obliterated. Thyroglossal duct 
in adult is indicated by foramen caecum.
1
 
ANATOMY 
 The thyroid gland typically consists of two lobes, a connecting 
isthmus and an ascending pyramidal lobe .One lobe, usually the  right 
may be smaller than the other .Isthmus is absent in about 10% of thyroid 
glands. Pyramidal lobe may be absent in 50% of cases. The thyroid gland 
normally extends from the level of 5
th
 cervical vertebra to the body of 1
st
 
thoracic vertebrae. It may be higher or slightly lower. 
Normal thyroid gland weighs about 30 gms  in adult, somewhat more in 
females than males. Each lobe is approximately 5 cm in length, 3 cm in 
width, 2-3 cm in thickness. Isthmus  is about 1.3 cm in breadth. The lobes 
have broader lower portion and conical apex. 
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 Thyroid gland comprises of true and false capsule. True capsule is 
from the connective tissue of gland and false capsule is from the pre-
tracheal fascia. Thyroid gland has blood supply from superior thyroid 
artery and inferior thyroid artery and and also branches of tracheal and 
oesophageal arteries. They are drained by superior, middle and inferior 
thyroid veins.Superior and middle veins drain into the internal jugular 
veins, whereas the inferior vein drains into the brachiocephalic vein. 
 Lymphatic drainage of the thyroid gland is to the pretracheal, 
paratracheal nodes, upper and lower deep cervical nodes. Some lymph 
may drain directly to the thoracic duct. 
 Thyroid gland is innervated by branches derived from sympathetic 
trunk mainly from middle cervical ganglion and small contributions from 
the superior and inferior cervical ganglia.
2,3
 
PHYSIOLOGY 
 Thyroid gland plays a main role in the regulation of basal 
metabolic rate, calcium metabolism, somatic and psychic growth. This is 
done by the two main hormones T3 (tri-iodothyronine) and T4 
(thyroxine). Normal functioning thyroid produces approximately 80% of 
T4 and about 20% of T3, but T3 is more potent than T4. 
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 These thyroid hormones secretions are regulated by hypothalamic 
–pituitary –thyroid axis. Thyroid hormone release is controlled by the 
thyrotrophin releasing hormone from the hypothalamus and by the 
thyroid stimulating hormone produced by the pituitary gland. Thyroid 
gland also produces calcitonin from the c –cells, which  plays a major 
role in regulating calcium level in the body 
4
. 
HISTOLOGY 
 Thyroid gland is covered by a fibrous capsule and the glands are 
divided into lobules by the septa arising from the fibrous capsule. The 
lobules are composed of follicles lined by cuboidal epithelial cells with 
central lumen filled with colloid. When the gland is in inactive or resting 
state the cells are flat to squamous and become columnar in hyperactive 
state. In interfollicular spaces parafollicular cells are seen, they may 
found singly or in groups. They are polyhedral in shape with eccentrically 
placed nuclei. Inter follicular spaces are filled with connective tissue, 
blood vessels and adipose tissue. 
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THYROID TUMORS : AN OVER VIEW 
 Carcinoma  of the thyroid are the most common endocrine tumors. 
Thyoid tumors are common in developed countries. Remarkably, the 
incidence of thyroid cancer has increased in the past two decades, 
predominantly attributable to an increase in papillary thyroid  
carcinomas
5
. Increased detection of even small tumors by imaging 
techniques, liberal criteria for diagnosis of papillary carcinoma of thyroid 
and environmental factors might play a part towards the increase in the 
incidence of the thyroid tumors
5,
 
6
. 
 According to the surveillance, Epidemiology, and End Results 
Study, 
7 
10 year survival rates of the major thyroid carcinomas are as 
follows :  
Papillary carcinoma-98% 
Follicular carcinoma-92% 
Medullary carcinoma-80% 
Undifferentiated carcinoma- 13% 
 In most of the cases surgery is the main stay of treatment. In 
tumors showing follicular differentiation, radioactive iodine and 
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suppressive thyroid hormone therapies are effective. In recent years 
Targeted therapies are also being used for resistant or advanced cases. 
GENERAL FEATURES OF PRIMARY THYROID CANCERS 
1.  The most common histological type is papillary carcinoma. 
2.  These tumors are two to four times more common in women than 
men.
8
 
3.  Females sex is associated with slightly better prognosis.
8
 
4.  Less differentiated tumors are occur in older individuals whereas 
younger patients have better differentiated tumors. 
5.  Age below 40 years have better prognosis than older patients
7
. 
6.  Apart from age, tumor size with staging is essential and important to  
determine the prognosis. 
DISTINCTIVE CHARACTERISTIC FEATURES OF THYROID 
CARCINOMAS IN CHILDREN 
1.  In children the most common histological type is papillary carcinoma. 
2.  Important risk factor –radiation exposure .For example Chernobyl 
nuclear accident
9
. 
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3. Thyroid carcinomas though aggressive in children, have better 
prognosis. 
4.  Children with lymph node metastasis are more prone for recurrence. 
FAMILIAL THYROID TUMORS 
 Twenty five percent  of tumors may occur in familial forms, not 
only in medullary carcinoma, but may also occur in non-medullary 
thyroid carcinoma. Particularly non medullary thyroid carcinoma is 
diagnosed in  two or more first degree relatives of patients with non 
medullary thyroid carcinoma.
10,11
 
Examples are 
1.  Familial multinodular goitre syndrome. chromosome involved -
14q31 [MNG-1] 
2.  Familial non-medullary thyroid carcinoma type-1 .chromosome 
involved -2q21 [NMTC-1] 
3.  Familial papillary thyroid carcinoma with renal papillary neoplasia. 
chromosome  involved-1q21[fptc/PRN] 
4.  Familial papillary thyroid carcinoma with or without oxyphilia. 
chromosome involved-19p13.2 [TCO] 
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WHO HISTOLOGICAL CLASSIFICATION OF THYROID 
TUMORS THYROID CARCINOMAS 
 Papillary carcinoma 
 Follicular carcinoma 
 Poorly differentiated carcinoma 
 Undifferentiated (anaplastic ) carcinoma 
 Squamous cell carcinoma 
 Mucoepidermoid carcinoma 
 Sclerosing mucoepidermoid carcinoma with eosinophilia 
 Mucinous carcinoma 
 Medullary carcinoma 
 Mixed medullary and follicular carcinoma 
 Spindle cell tumor with thymus-like differentiation 
 Carcinomas showing thymus -like differentiation 
THYROID ADENOMA AND RELATED TUMORS 
 Follicular adenoma 
 Hyalinising trabecular adenoma 
OTHER THYROID TUMORS 
 Teratoma 
 Primary lymphoma and plasmacytoma 
10 
 
 Ectopic thymoma 
 Angiosarcoma 
 Smooth muscle tumors 
 Peripheral nerve sheath tumors 
 Paraganglioma 
 Solitary fibrous tumor 
 Follicular dendritic cell tumor 
 Langerhans cell histiocytosis 
 Secondary tumors 
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SYNDROMES ASSOCIATED WITH THYROID NEOPLASM 
S.NO 
SYNDROME AND 
ITS INCICENCE 
GENE 
INVOLVED 
THYROID 
NEOPLASM 
1. Familial adenomatous 
polyposis 
 Incidence  2-14% 
APC[5q21] Most commonly 
papillary thyroid 
carcinoma -cribriform 
morular variant 
 2. PTEN-Hamartoma 
tumor 
[cowden syndrome] 
Incidence  >10 % 
PTEN[10q23.2] Papillary carcinoma 
and follicular 
carcinoma, rarely 
follicular adenoma 
3. Carney complex 
 Incidence -15 % 
PRKAR 
[17 q22-24] 
Follicular carcinoma 
and papillary 
carcinoma. 
occasionally benign 
follicular lesions 
4. Werner syndrome 
Incidence- 18% 
 
 
WRN [8p11-
12] 
Papillary carcinoma, 
follicular carcinoma, 
undifferentiated 
carcinoma and benign 
follicular lesions. 
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TUMOR , NODE, METASTASIS (TNM) STAGING OF THYROID 
TUMORS 
Tx  -  Primary tumor cannot be assessed 
T0           - No evidence of primary tumor 
T1           -Tumor size less than 2 cm in greatest dimension and  
     limited to  the thyroid. 
T2          - Tumor greater than 2 cm but less than 4 cm and limited to 
     the thyroid, without any extrathyroidal extension. 
T3         -Tumor greater than 4 cm in greatest dimension and the  
    tumor is limited to the thyroid or Any  tumor with minimal 
    extrathyroidal extension. 
T4a        - Moderately advanced disease 
     Tumor of any size extending beyond thyroid capsule  and 
     invades the subcutaneous  soft tissues,  larynx, trachea,  
     esophagus or recurrent laryngeal nerve. 
T4b       - Very advanced disease                                                      
     Tumor invades the prevertebral fascia or encases the  
     carotid artery or mediastinal vessels. 
13 
 
 Anaplastic carcinomas  -All are considered T4 tumors. 
                  T4a-  Intrathyroidal anaplastic carcinoma of any size 
     T4b- Anaplastic carcinoma with gross extra thyroidal  
              extension. 
REGIONAL LYMPH NODES( N ): 
NX        -  Regional lymph nodes cannot be assessed 
N0           - No regional lymph node metastasis 
N1           - Regional lymph node metastasis 
N1a         - Metastasis to Level VI ( pretracheal, paratracheal,  
     prelaryngeal or Delphian nodes) 
N2b         - Metastasis to unilateral, bilateral or contralateral cervical  
   ( Levels I,II,III,IV or V) or retropharyngeal or superior  
    mediastinal lymph nodes ( Level VII ) 
DISTANT METASTASIS  (M) 
MX        - Distant  metastasis cannot be assessed 
M0        - No distant metastasis 
M1        - Distant metastasis 
14 
 
STAGE GROUPING 
Stage groups are based on histological type and age. 
Papillary or follicular ( less than 45 years) 
Stage I      Any T Any N   M0 
Stage II    Any T Any NM1 
Papillary or follicular (greater than 45 years) 
Stage I        T1     N0    M0 
Stage II       T2     N0    M0 
Stage III       T3     N0   M0 
Stage III      T1      N1a  M0 
Stage III      T2      N1a M0 
Stage III       T3     N1a  M0 
Stage IV A    T4a   N0   M0 
Stage IV A    T4a   N1a  M0 
Stage IV A    T1    N1b   M0  
Stage IV A    T2    N1b   M0 
15 
 
Stage IV A   T3 N1b M0 
Stage IV A   T4a N1b M0 
Stage IV B    T4b Any N  M0 
Stage IV C    Any T   Any N   M1 
Medullary carcinoma : 
Stage I      T1 N0  M0 
Stage II     T2 N0 M0 
Stage II     T3 N0 M0 
Stage III    T1 N1a M0 
Stage III    T2  N1a M0 
Stage III    T3 N1a M0 
Stage IVA  T4a N0 M0 
Stage IVA  T4a N1a M0 
Stage IVA   T1   N1b M0  
Stage IVA  T2N1b M0 
Stage IVA  T3 N1b M0 
16 
 
Stage IVA  T4a N1 b M0 
Stage IVB   T4b Any N M0 
Stage IVC Any T   Any N  M1 
Anaplastic carcinoma ( all cases are stage IV ) 
Stage IVA T4a Any   N    M0 
Stage IVB T4b Any   N     M0 
Stage IVC    Any T  Any  N   M1 
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ROLE OF IMMUNOHISTOCHEMISTRY IN THYROID TUMORS 
 For most of the thyroid tumors, diagnosis can be reached by 
morphology alone. However, in tumors with morphological overlap as 
seen in follicular adenoma, follicular carcinoma and follicular variant of 
papillary carcinoma, diagnosis may be quite difficult. 
  Nuclear features characteristic of papillary carcinoma can also be 
seen in hyalinising trabecular adenoma and multinodular goitre with 
papillary hyperplasia. Certain tumors have overlapping  features and this 
may  result in diagnostic difficulty particularly tumors with follicular  
pattern  such as follicular variant of papillary carcinoma from follicular 
carcinoma and follicular adenoma. 
 The prognosis and the management is different in these thyroid 
tumors and hence it is essential to confirm for further management. Even 
follicular patterned lesions are identified based on the nuclear features 
like nuclear grooving, intranuclear pseudoinclusions and nuclear 
overlapping and  interobserver variations are not uncommon. Thus it may 
lead to inappropriate diagnosis/nomenculature. Hence in addition to the 
histopathological study of the tissue sections, inorder to overcome this 
difficulty many immunohistochemical markers are evaluated. These may 
really be  helpful in distinguishing papillary thyroid carcinoma from other 
follicular patterned lesions. 
18 
 
The more useful antibodies are thyroglobulin, calcitonin, TTF-1, PAX-8, 
cytokeratin 19, HBME-1, GALECTIN-3, CD 56 and recently beta-
catenin. . 
BETA-CATENIN: 
  β –catenin is a protein, in humans it is encoded by the CTNNB1 
gene. Beta –catenin is involved in regulation and coordination of cell-cell 
adhesion and gene transcription. It acts as an intracellular signal 
transducer in wnt signalling pathway .Mutation and over expression of 
beta-catenin are associated with many cancers, including colorectal 
carcinoma, hepatocellular carcinoma, malignant breast tumors, lung 
cancer and ovarian tumors. 
 In normal resting cells, beta-catenin forms membrane bound 
complexes with E-Cadherin . On  activation, beta-catenin translocates to 
cytoplasm and to the nucleus, thereby promoting the  tumor growth 
through activation of wnt signaling pathway
12
. Normal thyroid follicular 
cell shows strong immunoreactivity for beta-catenin. Thyroid tumors may 
show residual/weak membranous immunoreactivity and diffuse 
cytoplasmic and nuclear positivity of variable intensity. 
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THYROGLOBULIN: 
             Thyroglobulin is a glycosylated 330-kDa protein. It is a specific 
marker for thyroid follicular epithelial differentiation. It shows reactivity 
in follicular adenoma/carcinoma, papillary carcinoma, poorly 
differentiated thyroid carcinomas usually negative in undifferentiated 
carcinoma. Thyroglobulin is invaluable for confirming the thyroid origin 
of metastatic tumor. 
CALCITONIN: 
 It is a marker of parafollicular C cells. Calcitonin shows reactivity 
in medullary carcinoma and mixed medullary and follicular cell 
carcinoma. It is valuable for confirming the thyroid origin of metastatic 
tumor. 
TTF-1 
            Thyroid transcription factor-1, a 38-kDa nuclear protein that 
mediates thyroid specific gene transcription. It is normally expressed in 
thyroid follicular and parafollicular C cells, as well as in pneumocytes. 
TTF-is frequently positive in non squamous lung carcinoma.
13
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PAX-8 
 PAX-8 is a transcriptional factor involved in thyroid follicular cell 
development and expression of thyroid specific genes, also involved in 
kidney organogenesis. It shows reactivity in follicular adenoma/ 
carcinoma, papillary carcinoma, poorly differentiated thyroid carcinomas, 
medullary carcinoma and undifferentiated carcinoma. It shows 75% 
positivity. Metastatic renal cell carcinomas, B cell lymphomas are also 
show positivity.
13
 
CYTOKERATIN 19 
 Cytokeratin 19 is a 40 kDa protein belonging to the family of 
keratin. It is encoded by KRT 19 gene in human being. It is an 
intermediate filament mainly involved in protein binding, in maintaining 
the structural integrity of epithelial cells and organisation of myofibres. 
Cytokeratin 19 is widely used as diagnostic marker of papillary thyroid 
carcinoma. It is also expressed in basal keratinocytes, sweat glands, 
mammary gland ductal and secretary cells, gastrointestinal tract and 
ectocervix epithelium.
14
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HBME-1 
   A marker of mesothelial cells, named after laboratory of 
Dr.Hectorbattifora and Mesothelioma is a monoclonal antibody, which 
mainly  act against the antigen on the mesothelial cell membrane. It is 
expressed in papillary and follicular carcinomas
15
.  
GALACTIN-3 
       It is 33kDa protein belongs to lectin family. It is encoded by the 
LGALS3 gene located in chromosome 14in the locus q21-22.It plays 
important role in the regulation of cell to cell interaction, cell migration 
and repair of cell damage. It is helpful in distinguishing papillary 
carcinoma-follicular variant and follicular carcinoma from follicular 
neoplasm.
16
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MALIGNANT THYROID TUMORS 
PAPILLARY CARCINOMA 
             It is most common endocrine malignancy showing follicular cell 
differentiation characterized by distinctive nuclear features. It affects any 
age with mean age of 40 years affecting predominantly females.90% of 
thyroid malignancy in children is papillary carcinoma.
8
 
GROSS APPEARANCE 
  Grossly most of the tumors are tan or white with infiltrative 
borders cut surface is firm and gritty. Cystic change is relatively 
common. Appears granular or shaggy due to the presence of papillae. 
Areas of fibrosis may be present. May show infiltration into 
perithyroidal skeletal muscle, adipose tissue and adjacent structures. 
Lymph nodes metastasis is usually solid whitish and firm lesion, rarely 
as a cystic lesion.
17
 
MICROSCOPIC PATHOLOGY 
 Usually infiltrative lesion but can be well circumscribed  and 
encapsulated lesion. Multiple different architectural pattern may seen 
within the same tumor as papillary, solid, trabecular, macrofollicular, 
microfollicular and cystic pattern. 
23 
 
 Typically have branching papillae with delicate arborizing fronds 
with fibrovascular cores. Stroma of the papillae may be edematous, loose, 
hyalinised or myxoid. Follicles are often present containing thick colloid. 
Characteristic nuclear features may be present in majority of tumor cells. 
It includes nuclear crowding with overlapping of the adjacent nuclei, pale 
or clear chromatin, irregular nuclear membrane, grooves, intranuclear 
cytoplasmic inclusions. Another typical feature is the presence of 
psammoma bodies. These are small round deep purple laminated 
calcifications. Psammoma bodies are not pathognomonic of papillary 
carcinoma of thyroid but a typical feature.
18,19
 
 Grading of papillary carcinoma is not important because papillary 
carcinoma by definition it is a well differentiated, some authors found 
that papillary carcinoma with mitotic activity more than 4 per 10 high 
power field and necrosis is more clinically aggressive one.Papillary 
carcinoma may be  multifocal in 50% of cases
20
. Lymphatic invasion is 
most commonly seen. 
VARIANTS 
 Many histopathological variants of papillary thyroid carcinoma 
exist, some of them are found in combination.  
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Classification of papillary thyroid carcinoma (base on WHO 2004). 
Clear cell 
Columnar 
Cribriform morular 
Diffuse sclerosing 
Follicular  
Macrofollicular 
Microfollicular 
Microcarcinoma 
Oncocytic or oxyphilic 
Solid 
Tall cell 
Warthin –like 
Hobnail type 
 
 
25 
 
Clear cell variant: 
              These are uncommon variant with papillary or follicular 
architecture cells have vacuolated clear cytoplasm, some may appear 
oncocytic but nuclear features are in favour of conventional papillary 
carcinoma.
21
 
 Columnar cell variant: 
 These are rare aggressive variants with pseudostratified columnar 
cells with eosinophilic cytoplasm, nuclei are hyperchromatic 
characteristic papillary carcinoma thyroid nuclear features are rarely seen. 
Extrathyroidal extension and metastasis are more common. Metastasis are 
confused with metastasis from GIT, lung or endometrial sites. 
Cribriform morularvariant : 
 These are very rare tumor, 0.1 to0 .2 % of all papillary carcinoma 
of thyroid and they are usually associated with Gardner syndrome or 
familial adenomatous polyposis.Cribriform features, squmaoid morules, 
focal papillary areas and spindled areas may seen. Most nuclei are 
hyperchromatic but some may have clear nuclei and groove. They show 
nuclear positivity for β- catenin.
22,23
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Diffuse sclerosing variant: 
 Most common in young patients and associated with BRAF 
mutation. Diffuse involvement of one or both thyroid lobes with 
extrathyroid extension may be seen. Stromal fibrosis, lymphocytic 
infiltration and Psammoma bodies are abundant.
24
 
Follicular variant: 
             It is the most common variant of papillary carcinoma of thyroid 
composed of irregularly shaped follicles with few papillary structures. 
Psammoma bodies and intranuclear inclusions are rarely seen. 
Immunohistochemistry may be useful in differentiating these variant from 
follicular adenoma and follicular carcinoma.
25,26,27
 
Macrofollicular variant: 
 Rarest variant of papillary carcinoma of thyroid composed of 
macrofollicles usually >250 micrometers, nuclear  features are similar to 
that of papillary carcinoma of thyroid. Lymph node metastasis are 
uncommon with this variant.
28
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Micro carcinoma: 
              Size of the tumor will be less than 1 cm, may show features of 
any variant but this must be distinguished  from intrathyroid spread. 
Oncocytoma: 
              Grossly it has characteristic mahogany brown colour. 
Microscopically they have papillary or follicular pattern cells are 
polygonal in shape with apically located nuclei having eosinophilic 
granular cytoplasm.
29
 
Solid variant: 
 More common in children. In this variant the cells are arranged in 
sheets with characteristic papillary carcinoma features. It should be 
distinguished from insular /poorly differentiated carcinoma 
Tall cell variant: 
 This is a are less common but aggressive variant cells having 
height twice its width. Nuclear features are in favour of conventional 
papillary carcinoma, but centrally located having granular cytoplasm. 
Typically show extrathyroidal extension and lymph nodal metastasis. 
BRAF mutation seen in 80% of cases.
30
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Warthin like variant: 
 This type will have predominantly lymphoid stroma and the cells 
are elongated having eosinophilic cytoplasm. The immunoprofile of the 
lymphoid stroma is similar to chronic lymphocytic thyroiditis.
31
 
Hobnail variant: 
 These are rare but aggressive variant with complex papillary and 
micropapillary architecture. The lining epithelium will be cuboidal 
having increased nuclear to cytoplasmic ratio. Nuclei apically placed, 
producing a bulge that leads to hobnail pattern, areas of cellular 
dyscohesiveness may seen
32
. Usually associated with angiolymphatic 
invasion. 
Cytogenetics: 
 Molecular analysis has demonstrated translocation, inversions and 
chromosomal rearrangements involving the receptor tyrosine kinase gene. 
RET in approximately 20% to 30 % of papillary carcinoma of thyroid. 
Half of the papillary carcinoma of thyroid patient have point mutation in 
BRAF with substitution of valine to glutamate at residue 600( 
V600E).About 10% of cases harbour chromosomal rearrangements of the 
TRK gene.
33,34
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 In these , BRAF mutation analysis prove to be the most clinically 
relevant one. BRAF mutation are not found in other well differentiated 
tumors. Mutation involving these usually associated with extra thyroidal 
tumor extension and tumor recurrence
35
. BRAF mutation are commonly 
found in classical papillary carcinoma thyroid, tall cell variant and about 
10% of follicular carcinomas. 
IMMUNOHISTOCHEMISTRY 
 Although immunohistochemistry may rarely needed for diagnosis, 
it is useful for differentiating follicular variant of papillary carcinoma of 
thyroid from follicular carcinoma and follicular adenoma. Most useful 
markers in these settings are HBME-1, galectin-3, CK -19.Other markers 
that shows  positivity  are pancytokeratin, cytokeratin 7, thyroglobulin, 
and TTF-1. cytokeratin 20, calcitonin, CEA and neuroendocrine markers 
are negative in these tumors. 
PROGNOSIS: 
 The prognosis for papillary thyroid carcinoma is excellent.10 –year 
survival rate approaching 100% for younger patients and greater than 
90% for overall. Patients older than 45 years typically have more 
aggressive tumors. The American joint committee on cancer (AJCC) 
staging system reflects this age related difference. Vascular invasion and 
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nuclear atypia are poor prognostic signs. Variants such as tall cell, 
hobnail, diffuse sclerosing and columnar cell variant are associated with 
poor prognosis
36,37
. BRAF mutation is seen in more aggressive tumor. 
FOLLICULAR CARCINOMA 
 Follicular carcinoma account for 10% to 15 % of thyroid 
malignancy
38
.It shows evidence of follicular cell differentiation. Pre-
existing thyroid disease is present in upto 15 % of patients with follicular 
carcinoma. More common in women with age group more than 5th 
decade. 
It has 2 two types with different clinical behaviour 
1. Minimally invasive carcinoma 
2. Widely invasive carcinoma 
GROSS FEATURES 
 It usually occur as a solitary lesion with encapsulation ranging in 
size from 1 – 10 cm in diameter. cut surface will be tan to light brown. 
Minimally invasive carcinoma has thick fibrous capsule and grossly 
indistinguishable from follicular adenoma. Widely invasive carcinoma 
lacks capsule or extensive permeation of the capsule. 
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MICROSCOPIC PATHOLOGY 
 Diagnosis of follicular carcinoma rests on demonstration of 
capsular or vascular invasion. 
Criteria for capsular invasion
39,40
 
1. Tumor bud has invaded beyond the outer contour of capsule. 
2. Presence of satellite nodules with cytoarchitectural and cellular 
features, which is identical to those tumor cells. 
3. Tumor bud within the thin tumor capsule, however, it extended through 
outer capsule. 
4. Classical mushroom like bud that has totally traversed the fibrous 
capsule. 
Criteria for vascular invasion
39,40
 
1. Involved blood vessels must be located within or outside the fibrous 
capsule and not within the tumor. 
2. Intravascular tumor growth must be covered by endothelium and 
attached to the vessel wall associated with thrombus. 
3. Clusters of epithelial cells floating  in the vascular lumen are not 
considered vascular invasion. 
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 Extrathyroidal extension with invasion into the adipose tissue or 
skeletal muscle outside the limits of thyroid may occur. Nodal metastasis 
may occur to ipsilateral or contralateral nodes. High cellularity is seen 
with solid, trabecular or microfollicular growth pattern. 
Main feature of malignancy is vascular or capsular invasion irrespective 
of cytological atypia, growth pattern or mitotic activity. 
Molecular genetics 
 Mutation in RAS, PTEN, PIK3CA are found in follicular thyroid 
carcinoma than the follicular adenoma
41
. Additional mutations such as 
TP53, may be associated with progression to poorly differentiated 
carcinomas.20% of follicular thyroid carcinoma show rearrangements of 
peroxisome proliferator activated receptor gamma(PPARγ). Translocation 
involving  t (2;3)q13;p25 leads to fusion of PAX8 and PPARγ  can be 
detected by FISH.
41
 
IMMUNOHISTOCHEMISTRY 
            Immunohistochemistry is usually not required but tumors with 
unusual morphological features such as thick fibrovascular septa, clear 
cells, or hyalinising trabecular pattern may need mainly to confirm the 
follicular nature of the neoplasm. Most useful markers in these settings 
are HBME-1, galectin-3, thyroglobulin, tissue polypeptide antigen. They 
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are reported to show differential staining of follicular adenoma and 
follicular carcinoma.
42 
PROGNOSIS 
 If the disease is confined to thyroid cure rate will be 70 to 80%.20 
to 30% chance of recurrence, if regional lymph node metastasis are 
present.50 to 90% of patients who present with distant metastasis have  
increased mortality.
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POORLY DIFFERENTIATED THYRIOD CARCINOMA 
 Malignant thyroid neoplasm showing  histological  features 
intermediate between differentiated and undifferentiated thyroid 
carcinoma. Thought to arise arise from pre-existing papillary or follicular 
carcinoma, some may arise  as a denovo neoplasm. Accounts  for less 
than 2 % of thyroid neoplasm. 
 Poorly differentiated carcinoma was diagnosed as an entity in 2004 
WHO classification of tumors of endocrine organs. International 
consensus was held in Turin, Italy in 2007 had set a criteria and an 
algorithmic approach for poorly differentiated carcinoma
44
. It was 
validated in 2010.It has been shown to reliably diagnose papillary 
carcinoma thyroid and helpful in assessing the prognosis of the patients. 
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GROSS PICTURE 
 It usually present as a solitary mass with pushing borders usually 
infiltrative, but may have thick capsule. Necrosis and haemorrhage are 
common. 
MICROSCOPIC PATHOLOGY 
 Microscopically  the tumor cells are arranged in solid, trabecular, 
or insular growth pattern. Individual cells are small cells with round to 
vesicular nuclei with absence of the conventional nuclear features of 
papillary carcinoma thyroid some of them have oncocytic or clear cells. 
Tumor may have atleast one of the following features 
1. Convoluted nuclei 
2. Tumor necrosis 
3. Mitotic activity >3/10 high power field 
Some may have associated papillary or follicular carcinoma or 
component of  anaplastic thyroid carcinoma . 
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IMMUNOHISTOCHEMISTRY 
 Tumor cells are positive for TTF-1, Cytokeratin, cyclin-D1 and 
PAX-8 in 80% of cases and increased Ki67 index.
45,46
 
MOLECULAR GENETICS 
 βcatenin and P53 mutation are present in anaplastic and poorly 
differentiated carcinomas, but not in well differentiated tumors
47,48
. 
NRAS mutation is seen in 50% of poorly differentiated tumors. 
PROGNOSIS 
 Prognosis depends upon clinical staging, presence or absence of 
tumor capsule. Presence of capsular invasion, large tumor (size> 4 cm) 
and age > 45 years are associated with poor prognosis. 
UNDIFFERENTIATED /ANAPLASTIC CARCINOMA 
 Anaplastic carcinoma constitutes about 2 to 4% of the primary 
thyroid tumors. Females are most commonly affected with age group 
greater than 70 years
49
. Usually, present as a rapidly enlarging mass with 
single or multiple hard and fixed nodules. Most of the patients with 
anaplastic carcinoma have long standing history of nodular hyperplasia. 
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MACROSCOPY 
 Grossly, anaplastic thyroid carcinoma is usually fleshy and tan 
white with areas of haemorrhage and necrosis, may replace most of the 
normal thyroid parenchyma. 
MICROSCOPIC PATHOLOGY 
 Microscopically it is composed of variable admixture of 
epithelioidcells, spindle cells and pleomorphic giant cells. Individual cells 
have moderate amount of eosinophilic cytoplasm and always show brisk 
mitotic activity with apoptosis. Residual, well differentiated carcinoma 
either follicular or papillary may seen associated with it. Extensive 
necrosis is seen. Sarcomatoid appearance in tumors is predominantly 
composed of spindle cells.
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IMMUNOHISTOCHEMISTRY 
 Vimentin, keratin & PAX-8 is positive in upto 80% of cases
51,52
. 
p53 and p63 is positive in 70% of cases. Ki-67 proliferative index is 
usually greater than 80%. Thyroglobulin and TTF-1 are almost negative. 
MOLECULAR GENETICS 
 BRAF and RAS mutation are present in both differentiated and 
undifferentiated components. Most important and consistent findings is 
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association with ATC and TP53 mutation
53
.β catenin mutation is seen in 
80% of cases with  abnormal localisation of β catenin in nuclei due to 
altered degradation
54
. 
PROGNOSIS 
 Over all prognosis is poor with mortality rate is greater than 
90%.Mean survival after diagnosis is only six months overall survival 
ranges from 0-14%. Metastasis to distant sites are common mostly to 
lungs ,bone and brain. 
MEDULLARY CARCINOMA THYROID 
 Medullary carcinoma of thyroid is a neuroendocrine  tumor derived 
from the parafollicular  C cells of thyroid constituting 5- 10% of thyroid 
malignancy
55
. Medullary carcinoma of thyroid measuring less than 1 cm 
in diameter are called medullary microcarcinoma. It may be sporadic or 
part of MEN 2Aor 2B.MEN 2 is caused by mutation in RET gene. In 
hereditary medullary carcinoma of thyroid neoplastic C cell hyperplasia 
is a precursor lesion and are bilateral.
56
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GROSS PICTURE 
 Grossly present as unencapsulated but well circumscribed 
lesion,with cut surface is firm ,yellow and gritty. Typically present at the  
junction of upper and middle one third of the lobe .Sporadic tumors 
present as a solitary mass with or without involvement of lymph node. 
Hereditary tumors are usually multicentric and bilateral. 
MICROSCOPIC PATHOLOGY 
 Microscopically , it shows great variability. The typical features are 
cells may arranged in sheets, nests and trabecular pattern. Individual cells 
are round to oval with moderate amount of eosinophilic or amphophilic 
cytoplasm. Nuclei are round to oval with coarse  and granular chromatin 
and nucleoli are usually not prominent. Most of them show amyloid in 
stroma and are stained  by congo red. Staining for calcitonin is useful in 
making a distinction between medullary carcinoma of thyroid and tumors 
it may mimic.
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Variants 
1. Follicular 
2. Papillary or pseudo papillary 
3. Spindle cell like 
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4. Clear cell  
5. Oncocytic 
6. Giant cell 
7. Melanotic 
8. Paraganglioma like 
 Neoplastic C cell hyperplasia is precursor lesion for medullary 
carcinoma thyroid, most commonly seen in hereditary cases. It is 
characterised by enlarged, intrafollicular atypical C cells that may destroy 
the normal follicular epithelium. Neoplastic C cell hyperplasia progress 
into medullary carcinoma when the C cells extend into the stroma
58
. 
Sometimes it is difficult to differentiate C cell hyperplasia from 
microcarcinoma, but nuclear pleomorphism, stromal sclerosis, amyloid 
deposition, expansile growth pattern are helpful to differentiate it from 
former. 
IMMUNOHISTOCHEMISTRY 
 C cells and tumor cells shows positivity for calcitonin, 
synaptophysin, chromogranin-A, and CEA, but shows negativity for 
thyroglobulin
59
.A diagnosis of medullary carcinoma should always  be 
confirmed by immunohistochemistry, because of significant implications 
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of the diagnosis. Tumors which closely resembles medullary carcinoma 
of thyroid are thyroid paraganglioma ,follicular adenoma ,follicular 
carcinoma, oncocytic tumors, poorly differentiated carcinomas .For these 
immunohistochemistry may be useful . 
MOLECULAR GENETICS 
 Whether sporadic, non MEN familial or associated with MEN 2A 
or 2B , it is strongly associated with activating point mutation of the RET 
proto –oncogene. Recent studies show that mutation in RET 
protooncogene correlates with age of onset and aggressiveness of the 
medullary carcinoma of the thyroid
56
. Treatment with clinical trails of 
tyrosine kinase inhibitors targeting the RET kinase have shown to be 
useful in reducing the tumor burden in case of metastasis. 
PROGNOSIS 
 Overall 5 to 10 year survival rate is 60 to 80%. Better prognostic 
factors are tumorstage, young age, women and familial forms. Poor 
prognostic factors are squamous metaplasia, necrosis, less than 50 % , 
calcitonin immunoreaction and CEA reactivity
59,60
 . 
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MUCOEPIDERMOID CARCINOMA 
 Primary mucoepidermoid carcinoma is rare one arising from 
thyroid. Females are more commonly affected than men. Cell of origin is 
from ultimobranchialbody, few studies insisted that it is from thyroglossal 
duct. 
 Papillary carcinoma may co-exist with mucoepidermoid  
carcinoma, few cases in association with follicular carcinoma are also 
reported. Microscopically the tumor is not well circumscribed. The tumor 
cells arranged in islands in a sclerotic background, few of the tumor cells 
have intracytoplasmic mucin, comedo type of necrosis, nuclear 
pleomorphism and hyperchromasia. Psammoma bodies may seen. 
IMMUNOHISTOCHEMISTRY 
TTF-1, cytokeratin and thyroglobulin are positive
61
. 
SCLEROSING MUCOEPIDERMOID CARCINOMA WITH 
EOSINOPHILIA 
 It is a low grade malignant thyroid tumor with squamous cell and 
mucous cell differentiation with prominent sclerotic stroma and 
eosinophilic rich inflammatory infiltrate, almost exclusively occuring in 
females. 
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 Tumor grossly appear as an illdefined, yellow to white, firm solid 
mass. Microscopically present as circumscribed to infiltrative mass, 
containing cords and islands of tumor cells infiltrating in dense sclerotic 
stroma .Stroma is infiltrated by eosinophils, lymphocytes and plasma 
cells. Lymphnode metastasis may closely resembles Hodgkin lymphoma. 
Intracytoplasmic and intra luminal mucin may seen. Prognosis is 
excellent if extrathyroidal extension is not present 
IMMUNOHISTOCHEMISTRY 
Cytokeratin , TTF-1  and p63 are positive in these tumors
 62
. 
MUCINOUS CARCINOMA 
 Primary mucinous carcinoma of thyroid  is very rare .Only few 
cases has been reported in the literature .Metastasis occurs early and 
mean survival is only 4 months to 6 years. Histopathological feature will 
be similar to colloid carcinoma occurring in other sites. TTF-1 and 
thyroglobulin are positive in these tumors 
MIXED MEDULLARY CARCINOMA AND FOLLICULAR 
CARCINOMA 
 It is also called as differentiated carcinoma of intermediate type or 
follicular – para follicular carcinoma. It usually arises from stem cells 
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hence , shows dual component. Grossly they are unencapsulated having 
both medullary carcinoma along with follicular pattern. It may also 
arranged in trabecular, cribriform, nests and solid pattern. Few cases may 
have amyloid deposition. Thyroglobulin and calcitonin are positive in 
these tumors. 
SPINDLE CELL TUMOR WITH THYMUS LIKE 
DIFFERENTIATION 
 Spindle cell tumor with thymus like differentiation (SETTLE)is 
characteristically present in young patients. Grossly encapsulated or 
infiltrative with cut surface showing a lobulated grayish white to tan 
mass. It has biphasic growth pattern, showing spindled shaped cells with 
glandular structures, which mimic thymic differentiation. It shows strong 
positivity for cytokeratin. 
CARCINOMA SHOWING THYMUS –LIKE DIFFERENTIATION 
 Primary thyroid gland malignant neoplasm with cytologically and 
architecturally similar to thymic neoplasm.It arise from remnants of 
bronchial pouch capable of thymic differentiation. Tumour is composed 
of squamoid and focally spindle shaped cells with eosinophlic cytoplasm. 
Thymic like tissue with Hassall corpuscles may seen. 
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Immunohistochemically they show positivity for HMWK, P63, CEA. 
They show negative for TTF-1, thyroglobulin and calcitonin. 
TUMORS OF HAEMATOLYMPHOID CELLS 
 Primary lymphoma thyroid constitute about 5% of all thyroid 
neoplasm and 3 to 7% of extra nodal lymphomas. Almost always of B 
cell linage. Age group affected will be greater than 60 years and females 
are more commonly affected usually associated with lymphocytic 
thyroiditis. 
GROSS 
 Grossly present as unilateral or bilateral lesion with soft to firm in 
consistency cut surface is smooth bulging, white –gray or red with fish 
flesh appearance. Extension into perithyroidal adipose tissue or skeletal 
muscle is common. 
MICROSCOPIC PICTURE 
 Lymphomas of thyroid include extra nodal marginal zone B cell 
lymphoma(EMZBCL),diffuse large B cell lymphoma (DLBCL)and 
transition between the two. 
 Features of EMZBCL are diffuse to nodular heterogenous Bcell 
infiltrate with atypical small lymphocytes, immunoblasts, monocytoid  B 
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cells and plasma cells. The characteristic lymphoepithelial lesion are 
rounded balls with distension of  the lumen of the thyroid follicle-MALT 
balls. 
 Features of DLBCL Diffuse infiltration of cells composed of 
centroblasts, immunoblasts, monocytoid B cells and plasmacytoid cells. 
Increased mitotic activity and perithyroidal extension may commonly 
seen. 
IMMUNOHISTOCHEMISTRY 
 They show positivity for CD20 and CD79a.Cytokeratin highlights 
epithelial component in lymphoepithelial lesion. 
METASTATIC MALIGNANT TUMORS IN THYROID 
 Thyroid has rich blood supply hence metastasis to thyroid is 
common. Metastasis from lung adenocarcinoma, malignant melanoma, 
renal cell carcinoma, carcinoma breast, and sarcoma may occur. 
Sometimes papillary arrangement with psammoma bodies may be 
misinterpreted as papillary carcinoma. 
 Tumor metastasis from neuroendocrine carcinoma of bronchus and 
intra- abdominal site may present as a solitary or multiple nodules in the 
thyroid gland. Nuclear features may in close resemblance with medullary 
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carcinoma usually metastatic carcinomatous deposits present as a 
multiple nodules with increased vascularity and haemorrhage. 
Immunohistochemistry may be useful in differentiating these tumors. 
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MATERIALS AND METHODS 
Study design: 
Prospective study 
Study period: 
From June 2016 to May 2017 
Study place: 
Coimbatore medical college hospital, Coimbatore 
Sample size: 
Total number of cases-30 
Brief clinical data were collected from the case records age, sex, clinical 
diagnosis, surgical procedure done and FNAC details if done are noted 
from the records. 
Inclusion and exclusion criteria were applied  
Inclusion criteria: 
1. All thyroidectomy specimens  which includes total thyroidectomy, near 
total thyroidectomy, subtotoal thyroidectomy, hemithyroidectomy. 
2. Both male and female patients 
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3. All age are included 
Exclusion criteria 
Benign lesions of thyroid  
METHODS 
 As per the inclusion criteria a total of 30 cases were taken for the 
study. All those 30 cases reported as carcinomas were evaluated further 
with immunohistochemical analysis .initially after receiving the  
specimens they  were fixed in 10% formalin .after processing they were 
embedded in paraffin block and stained with eosin and hematoxylin. 
EOSIN AND HEMATOXYLIN STAINING PROCEDURE 
Reagent used 
1. Eosin Y -1% solution 
2. Hematoxylin –Erhlich ‘s hematoxylin 
3.1% acid alcohol 
PROCEDURE 
1. Sections are deparaffinized by using xylene -30 sections  
2. Sections are placed in isopropyl alcohol -15 minutes 
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3. Sections are washed in running tap water  
4. Stain in Erhlich’ s hematoxylin for 15 minutes 
5. Differentiate with 1% acid alcohol in two to three dips 
6. Blueing is done for 15 minutes 
7. Counter stain with eosin in two to three dips 
8. Wash in running tap water  
9. Air dry the section 
10. Mount the slide with DPX 
After staining, the slides were reported by the pathologists and 
categorized as the following 
1. Papillary carcinoma  
2. Follicular variant of papillary carcinoma of thyroid 
3. Cribriform morular variant of papillary carcinoma of thyroid 
4. Hobnail variant of papillary carcinoma of thyroid 
5. Follicular carcinoma 
6. Medullary carcinoma 
7. Poorly differentiated carcinoma 
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IMMUNOHISTOCHEMISTRY –PROCEDURE 
 From the selected cases blocks were taken .They were cut and 
mounted on the poly l lysine coated slides. Endogenous peroxidase 
activity was blocked with 0.3% hydrogen peroxide in methanol. Next 
antigen retrieval was done by heating in microwave oven by using Tris –
EDTA buffer at pH 7.5. The study was done using beta –catenin, a 
monoclonal antibody. 
PRINCIPLE  
 Immunohistochemistry is  used to analyse the expression of protein 
in the context of tissue morphology. Hence it identifies the presence 
and pattern of expression in a given section through specific antibody 
binding. 
 It is a two step indirect technique in which the sections of the 
tissues are first fixed and attached to the glass slides. After dewaxing the 
paraffin embedded sections antigen retrieval procedure is done .This is 
done by heating the formalin fixed sections in microwave oven in a 
selected buffer solution with appropriate pH. This will recover the full 
antigenicity with the most of the antibodies and these also helpful in 
retrieval of the antigenicity that were previously masked in formalin fixed 
tissue. Then the sections are treated with peroxidase block for blocking 
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the endogenous peroxidase and other non specific protein interactions. 
After treating with primary antibody, it will result in binding of these 
antibody to specific antigen, subsequently secondary antibody (HRP 
enzyme label) is conjugated to the primary antibody. Once the HRP 
molecules are bound, they catalyze the DAB substrate and chromogen 
creating  a reaction product precipitate at the site, which is visible by the 
light microscopy. 
REAGENTS USED: 
1.  Peroxidase blocker- 3% hydrogen peroxide in water. 
2.  Primary antibody- beta catenin (Rabbit monoclonal Antibody in 
PBS with carrier protein and preservative) 
3. Secondary antibody- HRP label reagent (Anti-mouse/rabbit 
horseradish peroxidase solution) 
4. Liquid DAB substrate: contains Tris buffer containing the 
peroxidase, antimicrobials and other stabilizers. 
5.  Chromogen :DAB -3,3’- DIAMINOBENZIDINE 
6.  Counter stain used- Ehrlichs’ s hematoxylin solution. 
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BUFFER SOLUTIONS: 
TRIS BUFFER:  
TRIS buffer salt- 0.605 gm 
Sodium chloride – 8 gm 
Distilled water -1000 ml 
1 N HCL- 2.5 ml 
TRIS –EDTA 
TRIS buffer salt- 6.05 gm 
Disodium EDTA- 0.744 gm 
Distilled water – 1000 ml 
STEPS: 
1. Sections are deparaffinised with xylene for 20 minutes as two 
exchanges 10 minutes each. 
2.  Sections are dehydrated with absolute alcohol for 5 minutes with two 
changes. 
3.  Sections are then washed in tap water for 5 minutes. 
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4.  Sections are then rinsed in distilled water for 5 minutes. 
5.  Antigen retrieval is done with Tris EDTA buffer solution by keeping it 
in the microwave oven for 450 degree Celsius for 15 minutes and 800 
degree Celsius for 15 minutes. 
6.  They are then kept in the room temperature to cool . 
7.  Sections are rinsed in distilled water 
8.  Sections are then treated with peroxidase block for 10 minutes. 
9.  Then the sections are washed in Tris Buffer saline for 10 minutes with 
two changes, each 5 minutes. 
10. Again the sections are treated with power block for 10 minutes 
11. The slides are then drained and covered with primary antibody for 
one hour. 
12. Again the sections are washed with Tris Buffer saline for 10 minutes 
with two changes, each 5 minutes. 
13. Then the sections are covered with HRP labelled secondary antibody   
for 30 minutes 
14. Again the sections are treated with Tris Buffer Saline for 10 minutes 
with  2 changes, each 5 minutes 
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15. Then the sections are treated with DAB chromogen with substrate 
buffer for 5 -7 minutes 
16. The sections are then rinsed in distilled water  
17. Sections are counterstained with hematoxylin for 20 seconds 
18. Then washed  in tap water for 5 minutes 
19. The slides are air dried  and mounted with DPX. 
RESULT: 
Positive-    If tumor cells have taken golden brown colour in membrane / 
cytoplasm /nucleus. 
Negative- If the tumor cells were not  stained as golden brown colour. 
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INTERPRETATION:In the present study Interpretation of cytoplasmic 
staining of Beta –catenin are done as below 
S.NO GRADING 
PERCENTAGE OF CELLS 
EXPRESSING BETA CATENIN 
1. 0  (Negative) No positively staining tumor cells 
2. 1+ (focally positive) Less than 25 % of cells  shows positivity 
3. 2+ (moderate  positivity) 25 – 50 % of cells shows positivity 
4. 3+(diffusely positive) Greater than 50% of cells shows positivity 
In the present study Membranous Staining of beta-catenin was graded as 
follows 
Proportion of 
staining 
Grading Corresponds to  membrane staining 
    No staining zero    negative 
<25 % 1+ Severe loss of membrane staining 
25%  - 50 % 2+ Moderate loss of membrane staining 
50%  - 75 % 3+ Mild loss of membrane staining 
75%  -100%          4+ Membrane staining of Normal thyroid 
follicular cells. No loss of membrane 
staining 
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OBSERVATION AND RESULTS 
 The  present study is a prospective study conducted in the 
Department of Pathology, Coimbatore Medical College and Hospital,  
Coimbatore. A total of  30 cases of thyroidectomy specimens for different 
thyroid tumors, received  over the period of  June 2016 to May  2017 
were studied. 
 After obtaining the Ethical clearance from the Ethical committee of 
Coimbatore  Medical College and Hospital, Coimbatore, the study was 
conducted. 
 We evaluated  30 thyroid tumors which include papillary 
carcinoma conventional type and few other variants of papillary 
carcinoma, follicular carcinoma, poorly differentiated carcinoma and 
medullary carcinoma. In these  thyroid tumors the histomorphological 
pattern and immunohistological pattern  of expression of beta- catenin 
were studied, analysed and compared with the  literature. 
 
 
 
 
57 
 
Table 1: Age distribution i thyroid tumors 
Age distribution Number of cases Percent (%) 
<30 YEARS 5 16.6 
31-50 YEARS 14 46.7 
>51 YEARS 11 36.7 
Total 30 100.0 
      In the present study the incidence of thyroid tumors is common  in the 
age  group between  30-50 years, constituting 46.7% of the total cases 
followed by  36.7% and 16.6% in age group  greater than 51 years and 
less than 30 years  respectively 
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         Table 2: Gender distribution of  thyroid tumors 
Gender distribution Number of cases Percent (%) 
Male 6 20.0 
Female 24 80.0 
Total 30 100.0 
         In the present study , thyroid tumors are more common among the     
females  constituting about 80% in contrast to male comprising only 
20%.Female to male ratio is 4:1. 
 
Chart 2 : Gender distribution of thyroid tumors 
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Table 3: Distribution of different thyroid tumors 
Types of Carcinoma Number of cases Percent (%) 
Papillary Carcinoma 22 73.4 
Follicular Carcinoma 4 13.3 
Medullary Carcinoma 
of Thyroid 
3 10.0 
Poorly Differentiated 
Carcinoma 
1 3.3 
Total 30 100.0 
  
           In the present study papillary carcinoma constitutes the majority of 
the cases ,  i.e 22 cases ( 73.4%) followed by follicular carcinoma  4 cases 
and medullary  carcinoma  3 cases constituting 13.3 % and 10 %  
respectively. 
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Chart 3:Distribution of different thyroid tumors 
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Table 4: Age distribution of thyroid tumors with metastasis 
Age distribution 
Metastasis 
(n=17) 
No Metastasis 
(n=13) 
<30 YEARS 3(17.7%) 2(15.4%) 
31-50 YEARS 4(23.6%) 10(77.0%) 
>51 YEARS 10(58.7%) 1(7.6%) 
 In the present study,  totally 17  cases have presented with  metastasis of 
which  59% of cases are above 50 years of age.   13 cases have no 
metastasis.  
Chart 4: Age distribution of thyroid tumors with metastasis 
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Table 5: Association of age in different thyroid tumors 
Age 
distribution 
Papillary 
Carcinoma 
n=22 
Follicular 
Carcinoma 
n=4 
Medullary 
Carcinoma 
of Thyroid 
n=3 
Poorly 
Differentiated 
Carcinoma 
n=1 
<30 
YEARS 
4(18.2%) 0(0.0%) 1(33.3%) 0(0.0%) 
31-50 
YEARS 
11(50.0%) 2(50.0%) 1(33.3%) 0(0.0%) 
>51 
YEARS 
7(31.2%) 2(50.0%) 1(33.3%) 1(100%) 
 In the present study papillary carcinoma is found to be more  
common in the age group  between 31-50 years constituting 50%, 
followed by the  age group greater than  51 years and less than 30 years 
constituting 31.2%  and   18.2%  respectively.  Follicular carcinoma is 
equal in the age group between 31-50 years and greater  than 51 years. 
Medullary carcinoma constitutes about 33.3% of  in each group in  the 
above age distribution. 
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CHART 5: ASSOCIATION OF AGE IN DIFFERENT THYROID   
TUMORS 
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Table 6:  Gender distribution in different thyroid tumors 
Gender 
distribution 
Papillary 
Carcinoma 
Follicular 
Carcinoma 
Medullary 
Carcinoma 
of Thyroid 
Poorly 
Differentiated 
Carcinoma 
Male 3(13.63%) 1(25%) 2(66.6%) 0(0.0%) 
Female 19(86.36%) 3(75%) 1(33.4%) 1(100%) 
  The present study, reveals that incidence of papillary carcinoma is more 
in females constituting 86.36%  compared to males which is 13.63%, 
followed by  follicular carcinoma constituting 75% and 25% in females 
and males respectively.  
CHART 6: GENDER DISTRIBUTION IN DIFFERENT THYROID 
TUMORS  
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Table 7: Metastasis with age distribution among patients with 
Papillary Carcinoma of thyroid 
Age distribution Metastasis 
n=11 
No Metastasis 
n=11 
<30 YEARS 2(18.2%) 2(18.2%) 
31-50 YEARS 3(27.3%) 8(72.7%) 
>51 YEARS 6(54.5%) 1(9.1%) 
In the present study   11   cases of papillary carcinoma of thyroid have  
presented with lymph  node metastasis of which  6 cases(54.5% )  are 
above 50  years of age.  11  cases have no metastasis.  
CHART 7: METASTASIS WITH AGE DISTRIBUTION AMONG 
PATIENTS WITH  PAPILLARY CARCINOMA  
 
 
66 
 
Table 8: Variants of Papillary Carcinoma and its age distribution 
Age 
distribution 
Papillary 
carcinoma 
-
cribriform 
morula 
variant 
(n=2) 
Papillary 
carcinoma 
-follicular 
variant 
(n=3) 
Papillary 
carcinoma 
-hobnail 
variant 
(n=1) 
Papillary 
carcinoma- 
conventional 
type 
(n=16) 
<30 YEARS 0(0.0%) 1(33.3%) 0(0.0%) 3(18.75%) 
31-50 
YEARS 
0(0.0%) 1(33.3%) 1(100%) 9(56.25%) 
>51 YEARS 2(100%) 1(33.3%) 0(0.0%) 4(25.0%) 
 In the present study , majority of conventional type of papillary 
carcinoma occur in the age group 31-50 years constituiting 56.25%(9/16 
cases),follicular variant of papillary carcinoma is found equally in all age 
groups (33.3% ) 1/3 cases. In cribriform morular variant both cases are in 
age group more than 51 years(100%) 2/2 cases. 
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CHART 8: VARIANTS OF PAPILLARY CARCINOMA AND ITS 
AGE DISTRIBUTION 
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Table 9:  Intensity of Cytoplasmic Staining of Beta Catenin in 
Thyroid Tumors 
Staining 
of Beta 
Catenin 
Papillary 
Carcinoma 
n=22 
Follicular 
Carcinoma 
         n=4 
Poorly 
Differentiated 
Carcinoma 
n=1  
Medullary 
carcinoma 
thyroid 
  n=3 
0 0(0.0%) 0(0.0%)  0(0.0%) 3(100.0%) 
1 1(4.6%) 1(25.0%) 0(0.0%) 0(0.0%) 
2 7(31.8%) 3(75.0%) 0(0.0%) 0(0.0%) 
3 14(63.6%) 0(0.0%) 1(100.0%) 0(0.0%) 
 
 
CHART 9: INTENSITY OF CYTOPLASMIC STAINING OF  
 
BETA –CATENIN IN THYROID TUMORS 
     
               Papillary             Follicular       poorly             Medullary 
               carcinoma          carcinoma     differentiated   carcinoma 
                                                                carcinoma 
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In the present study, staining intensity of beta-catenin in   papillary 
carcinoma of thyroid shows strong cytoplasmic positivity  in 63.6% of the 
cases.( i.e 3+  in 14 out of 22 cases of papillary carcinoma of 
thyroid).31.8 % of cases shows moderate cytoplasmic positivity  (i.e 2+ 
in  7 out of 22 cases) and 4.6% of cases shows weak cytoplasmic  
positivity of 1+( 1 out of 22 cases). 
Follicular carcinoma shows moderate cytoplasmic  positivity in 75% of 
cases ( i.e  2+ in 3  out of 4 cases) and weak cytoplasmic positivity  in 
remaining 25% of the cases(i.e 1+  in 1 out of 4 cases). 
In the present study, Poorly differentiated carcinoma  shows diffuse 
cytoplasmic staining (i.e 3+ positivity ) . 
Medullary carcinoma shows negativity for  cytoplasmic  staining in all 
the three cases studied.  
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Table 10:  Proportion of Membrane Staining of Beta Catenin in 
Thyroid Tumors 
Staining 
of Beta 
Catenin 
Papillary 
Carcinoma 
n=22 
Follicular 
Carcinoma 
n=4 
Poorly 
Differentiated 
Carcinoma 
n=1 
Medullary 
carcinoma 
thyroid 
n=3 
0 
 
0(0.0%) 0(0.0%) 0(0.0%) 3(100.0%) 
1 0(0.0%) 2(50%) 1(100.0%) (100.0%) 
2 10(45.4%) 2(50%) 0(0.0%) 0(0.0%) 
3 12(54.6%) 0(0.0%) 0(0.0%) 0(0.0%) 
 
CHART 10: PROPORTION OF MEMBRANE STAINING OF BETA –CATENIN IN 
THYROID TUMORS 
 
 
                     Papillary        Follicular          poorly               Medullary 
                     carcinoma     carcinoma        differentiated     carcinoma 
                                                                    carcinoma 
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In the present study , beta-catenin in papillary carcinoma of thyroid  
shows 3+  membranous  positivity   in 54.6% of cases (12 out of 22 
cases) and   2+membranous positivity in 45.45% of cases  (10 out 22 
cases). 
 Follicular carcinoma shows  membrane positivity of  1+  in50% of 
cases  (2  out of 4 cases) and membrane positivity of  2+ in remaining 
50% of cases (2 out of 4 cases). 
 In the present study, Poorly differentiated carcinoma show 1+ 
membranous staining  and medullary carcinoma shows  negative 
membranous staining  in  all the  cases studied .  
 
In overall, Papillary carcinoma show strong/moderate cytoplasmic beta 
catenin positivity and strong/moderate membrane positivity. In follicular 
carcinoma both cytoplasmic  and membrane positivity are moderate or 
less. Poorly differentiated carcinoma show strong/diffuse cytoplasmic  
positivity and very minimal membane positivity. 
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Table 11.statistical analysis  of cytoplasmic beta-catenin expression in  
papillary carcinoma thyroid with and without metastasis 
Papillary 
carcinoma 
Cytoplasmic 
staining 
3+ 
Cytoplasmic 
staining 
2+ 
P value 
With 
metastasis 
 
11 0   
.005* 
Without 
metastasis 
 
3  7 
*-Statistically significant (P<0.05) 
 Sensitivity=78%  
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Table 12.statistical analysis of  membranous expression of beta-
catenin in papillary carcinoma of thyroid with and without metastsis 
Papillary 
carcinoma 
 
Membranous  
staining 
2+ 
Membranous 
staining 
3+ 
P value 
With metastasis 
 
9 2  
0.004* 
Without 
metastasis 
 
 
1 
            
             10 
*-Statistically significant (P<0.05)  
Sensitivity -90% 
Specificity- 83%  
 
   MEMBRANOUS STAINING     MEMBRANOUS STAINING 
                    2+                                                  3+ 
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                                 DISCUSSION 
 Thyroid lesions are common worldwide and they are more 
common in females in the age group between 35 to 65 years. Globally as 
of 2015, 3.2 millon people have thyroid cancer. 
 Thyroid tumors are the most common endocrine tumors 
comprising 6 to 10 %.  Every year about 3.8% of new cases of thyroid 
cancer occur. Hence for better clinical management it is very essential to 
identify specific diagnosis, since incorrect diagnosis may lead to 
unnecessary stress for the patients and unwanted healthcare expenditure.  
Prognosis and followup may vary depending upon the thyroid tumors, 
hence it is necessary to  confirm the diagnosis for the better management 
of the patient. 
 Diagnosis of thyroid tumors by the usual hematoxylin and eosin 
stained sections may be sometimes a challenging one for the pathologist, 
because of the overlapping histological features in quite a number of 
thyroid tumors. Hence interpretation of these thyroid tumors particularly 
lesions with follicular pattern may be difficult. Similarly the characteristic 
nuclear features which are seen in papillary carcinoma of thyroid may not 
be present in all cases. 
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 Encapsulated tumors with follicular pattern and some of the 
follicular lesions with incomplete vascular or equivocal capsular invasion 
may result in dilemma in differentiating these tumors. 
 In  view of all these shortcomings, immunohistochemistry may be 
useful in distinguishing these lesions. Various immunohistochemical 
markers were used and analysed in previous studies. In this study, the 
usefulness of beta-catenin in differentiating the thyroid tumors and 
prognostic significance were analysed and it is correlated with age, sex 
and histomorphology. The observation and results of this study were 
compared with the previously conducted studies.  
 As per the study conducted by Farahati J et al in 1997 thyroid 
tumors  most commonly occurred in the age group between 30 to 60 
years.
8
 
 In our  study we also observed that thyroid Tumors were common 
in  the age group  30 to 50 years  .This is in accordance with the above 
study (Table 1). 
 Chen A Y et al in 2009, observed that thyroid tumors were more 
common in females when compared to males.
5
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 In our study, we also observed that incidence of thyroid tumors 
were more in females than males, with female to male ratio of 4:1 as 
shown in table 2. 
 According to the statistics released by National cancer institute in 
2013, papillary carcinoma is the predominant malignancy constituting 70-
80 % of all thyroid cancers followed by follicular carcinoma constituting 
10-15%.  
 In the present study we  obtained similar results with papillary 
carcinoma constituting  73.4%, followed by follicular carcinoma 13.3%.  
 In 2013, Fabio Muradas Girardi et al, did a retrospective study 
of prevalence of variants of papillary carcinoma of thyroid in a single 
centre. They found out that classic or  conventional type of papillary 
carcinoma to be the  common type constituting 31.7 %, followed by  
follicular variant and oncocytic variant constituting 16% and 1.9% 
respectively. Other variants of about 0.1 to 0.7 % only.
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 In our study, classic or conventional  papillary carcinoma of 
thyroid was found to be the most common type constituiting 72.7% 
followed by follicular and cribriform variant  comprising 13.6% and 9 % 
respectively. Hence, this correlates with the previous study which also 
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shows  predominance of conventional type of papillary carcinoma of 
thyroid. 
 S.Rezk et al, studied the diagnostic utility of beta-catenin  in 
thyroid lesions and observed that papillary carcinoma, follicular 
carcinoma and follicular variant of papillary carcinoma showed strong 
cytoplasmic / membranous staining and minimal residual membranous 
staining in 87%,80% and 71% respectively. They also observed that the 
intranuclear inclusions were distinctly positive in 83% of papillary 
carcinoma of thyroid and 20% of follicular variant of papillary 
carcinoma.
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  Ishigaki et al, in their study observed cytoplasmic 
/membrane immunoreactivity for beta –catenin in 67 % of papillary 
carcinoma and 25% in follicular carcinoma.
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 In this present study papillary carcinoma showed 2+ and 3 + 
membranous staining and cytoplasmic positivity varying from 1+(one 
case only) , 2+ (in some cases) and  3+(most of the cases). Follicular 
carcinoma show 1+ and 2 +  membranous positivity and 1+ and 2+ 
cytoplasmic staining. Poorly differentiated carcinoma show 1+ 
membranous positivity and 3+ cytoplasmic positivity.(Table 9 & 10) 
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  Papillary carcinoma  show strong/moderate cytoplasmic beta 
catenin positivity and strong/moderate membrane positivity. In follicular 
carcinoma both cytoplasmic  and membrane positivity are moderate or 
less. Poorly differentiated carcinoma show strong/diffuse cytoplasmic  
positivity and very minimal membane positivity. 
           Sethi K et al in 2011, in their study have  analysed beta-catenin 
and few other markers as a diagnostic and prognostic marker in thyroid 
carcinoma. They observed that the diagnostic accuracy of beta –catenin 
was 96% and 94% for the diagnosis of papillary thyroid carcinoma and 
follicular carcinoma respectively. They also observed that they were 
strongly expressed in invasive papillary carcinoma and follicular 
carcinoma.
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               In our study, among the 22 cases of papillary carcinoma 11 
cases had metastasis and other 11 did not have metastasis. On comparing 
the membranous and cytoplasmic staining between those with metastasis 
and those without metastasis, the following observation was found. Beta-
catenin membrane staining in papillary carcinoma with metastasis show 
2+ (corresponding to more  loss of membrane staining ) in 9 out of 11 
cases and 3+ (corresponding to less loss of membrane staining) in 2 out 
11 cases with metastasis. The cytoplasmic staining  in all the 11 cases 
with metastasis show 3+( strong/diffuse) cytoplasmic positivity. 
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             Among the 11 cases without metastasis 10 cases showed 3+ 
membranous staining (corresponding to less loss of membrane staining) 
and 1 case showed 2+ membrane staining(corresponding to more loss of 
membrane staining). Cytoplasmic staining was variable with 1+ in one 
case , 2+ in 7 cases and 3+ in 3 cases.(Table 11 & 12).The 3  cases 
without metastasis but with 3+(diffuse/strong) cytoplasmic positivity may 
behave aggressively and may need  more close follow up. 
 Junk C K et al in 2009, in their study, IHC of beta-catenin  found 
to be showing strong cytoplasmic and nuclear staining in cribriform 
morular variant of PTC, but in our study we observed  strong cytoplasmic 
with occasional nuclear positivity only.
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 Rossai D et al in 2013, observed that 80% poorly differentiated 
carcinoma showed immunoreactivity for beta-catenin, which seems to be 
related to a worse prognostic behaviour. They concluded that poorly 
differentiated carcinoma represents an intermediate step in the biological 
process of dedifferentiation towards anaplastic thyroid carcinoma. This 
shift was underlined by the beta-catenin expression and hence worse 
clinical behaviour.
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 In accordance with the above studies in this present study, we 
observed that poorly differentiated carcinoma shows strong/diffuse 
cytoplasmic staining with minimal membrane staining. This reduction of 
membranous staining is consistent with the progressive loss of 
intracellular adhesions that could be related to the invasive and hence the 
metastatic properties of thyroid cancer cells. 
 Hence the loss of beta- catenin membrane reactivity and its cytoplasmic / 
nuclear localisation has been found to correlate with loss of 
differentiation and poor prognosis. 
 In our study papillary carcinoma with metastasis show strong 
cytoplasmic positivity and moderate residual membrane positivity( i.e 
translocation of beta-catenin from membrane to cytoplasm) when 
compared with those without metastasis. These findings are consistent 
with invasive and metastatic properties of thyroid tumor. 
              So, in our study pattern of staining in different thyroid lesions is 
consistent with wnt signaling pathway via translocation of beta-catenin  
from the cell membrane to the cytoplasm/nucleus in malignant lesions. 
The specificity of beta-catenin as a prognostic marker with Chi square  
test of these variables showed significant p value <0.05.(Table 11&12) 
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                             SUMMARY AND CONCLUSION 
 The morphological distinction of thyroid follicular lesions can 
sometimes be a challenging one for the pathologists, and therefore an 
immunohistochemical  marker can be useful . Beta catenin is one such 
potential IHC marker. It plays a significant role in cell adhesion and 
promotion of growth through activation of wnt signalling pathway . 
Translocation of these membrane bound protein to cytoplasm/nucleus  
promotes transcription of genes, resulting in  cellular proliferation. 
        In this study, paraffin blocks from 30 thyroidectomy specimens were 
stained with monoclonal antibodies for beta-catenin. These included 22 
cases of papillary carcinoma of thyroid( 16cases of conventional papillary 
carcinoma of thyroid, 3 cases of follicular variant, 2 cases of cribriform 
morular variant, 1case of hobnail variant ), 4 cases of follicular 
carcinoma,3 cases of medullary carcinoma and 1 case of poorly 
differentiated carcinoma. Tissues from normal thyroid specimens served 
as control.  
          Papillary carcinoma conventional type, other variants of papillary 
thyroid carcinoma and follicular carcinoma expressed diffuse cytoplasmic 
and focal nuclear positivity with moderate to strong residual membranous 
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staining. Papillary thyroid carcinoma, follicular variant of papillary 
thyroid carcinoma and hobnail variant show few  nuclear inclusions 
staining positive for beta-catenin. 
        Poorly differentiated carcinoma show  strong/diffuse cytoplasmic 
positivity for beta-catenin and minimal with  membrane positivity.      
         Hence the loss of beta- catenin membrane reactivity and its 
cytoplasmic / nuclear localisation has been found to correlate with loss of 
differentiation and poor prognosis. 
          Papillary carcinoma with metastasis show strong cytoplasmic beta-
catenin positivity and moderate membranous positivity in most of the 
cases when compared with the cases without metastasis . 
This reduction of membranous positivity along  with more of cytoplasmic 
positivity is   consistent with the progressive loss of intracellular 
adhesions that could be related to the invasive and hence the metastatic 
properties of thyroid cancer cells. 
         The specificity of beta-catenin as a prognostic marker with Chi 
square  test of these variables showed significant p value <0.05. 
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              The above data  and  observations  lead to the conclusion that loss 
 of membrane positivity of beta catenin  with cytoplasmic and nuclear  
expression  correlate well with aggressive behaviour  i.e increased 
invasiveness and metastasis. 
 
 Further studies can be pursued with larger sample size and  panel 
of markers with close follow-up of patients, to predict the behaviour of 
thyroid tumors. 
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Figure 1: H&E section of papillary carcinoma of thyroid –conventional type. 
Low power view (10x). 
 
 
 
 
   Figure 2: H&E section of papillary carcinoma of thyroid .High power view( 40x) 
 
  
 
 
 
 
 
 
 
 
Figure :3 IHC- papillary carcinoma conventional type shows residual membranous and  
cytoplasmic staining of beta-catenin. occasional nuclear inclusions positivity(arrow) .                                               
Low power view(40x). 
 
 
Figure 4: papillary carcinoma conventional type shows strong cytoplasmic and residual 
membranous positivity of beta – catenin .High  power view ( 40x ). 
 
 
. 
 Figure 5 :IHC- papillary carcinoma of thyroid shows diffuse cytoplasmic and residual 
membrane positivity shown in oil immersion(100x) 
 
 
 
 
 
 
 
 
 
 
 
 
  Figure 6:Follicular variant of papillary carcinoma of thyroid showing strong     
cytoplasmic and residual membranous staining of beta-catenin. Focal nuclear 
 positivity also seen(arrow). Low power  view(40 x). 
..                    
Figure 7 : H& E section of Hob nail variant of  papillary carcinoma of thyroid        
                     High power view(40x). 
 
 
           
           
           
           
           
           
           
           
           
          
  
 
 
 
 
 
 
Figure :8 IHC- Hobnail variant of papillary carcinoma of thyroid shows residual 
membranous and cytoplasmic staining . High power view (40x).Inset picture shows   
distinct  nuclear inclusion positivity. 
 Figure 9 :H&E section shows cribriform morular variant of papillary carcinoma of 
thyroid. Low power view (10x). 
 
 
Figure 12 : IHC- Cribriform morular variant of papillary carcinoma shows loss of 
membrane positivity ( arrows) with focal areas  of strong cytoplasmic positivity 
( arrow heads) High power view (40x). 
 
 
  
Figure 13: H&E section of follicular carcinoma of thyroid .High power view (40x). 
          
 
Figure 14: IHC- follicular carcinoma of thyroid shows moderate  cytoplasmic 
positivity with focal areas of residual membranous positivity . 
oil immersion view(100x). 
 Figure 15 : H&E section of poorly differentiated carcinoma. High power 
view(40x) 
 
 
Figure 16:IHC- Diffuse cytoplasmic staining of beta-catenin in poorly 
differentiated carcinoma of thyroid. High power view (40x). 
                           Figure 17: H&E Section of medullary carcinoma of thyroid.  
                                             High power view (40x). 
 
 
Figure 18:  IHC- Medullary carcinoma of thyroid shows negative staining 
                    beta-catenin. Low power view (10x)  
 
ANNEXURE 1 
PROFORMA 
Coimbatore medical college 
Department of   Pathology 
Coimbatore 
Particulars of the patient: 
Name  :                                                       Age: 
Unit    :                                                       In patient  Number :                                         
Presenting complaints: 
Pain  
swellinginfront of the neck 
Onset and progression                                            
Difficulty in swallowing 
Hoarseness of voice  
Altered  Bowel habits 
Menstrual history in  female 
Hypo/ hyperthyroidism symptoms 
Loss of  appetite and weight                                                                   
Past history: 
History of radiation exposure to head and neck 
History of previous surgeries (if any ) 
Family history 
Personal history: 
Diet 
Smoking and alcoholic 
General examination:              
Nourishment :                    Built:                                               
Conscious:       Pallor:                                  
Jaundice:         Clubbing: 
Febrile/afebrile                  Pedal edema 
Tremors:                            Eye signs: 
Lymphadenopathy 
Vitals: 
Pulse rate:                      
Blood pressure        :                
Respiratory Rate     :        
Local examination:             
Site :                                    Size:   
Multinodular / Solitary nodule 
Moving with deglutition or not  
Fixity to surrounding structures 
Cervical lymphadenopathy  
Any other palpable nodes  
 
Clinical diagnosis: 
 
Investigations: 
Thyroid  profile: 
USG  Report: 
Fine needle aspiration cytology report (FNAC): 
Microscopic findings: 
Histopathological diagnosis: 
Immunohistochemistry: 
FINAL DIAGNOSIS 
 
 
 
 
 
 
 
 
 
 
 ANNEXURE III- LIST OF ABBREVIATION 
 
HBME-1             -       Hector Battifora Mesothelial-1 
TTF-1                 -       Thyroid transcription factor -1 
EMA                  -        Epithelial membrane antigen 
CEA                   -       Carcinoembryonic antigen 
NSE                   -       Neuron specific enolase 
PC                       -       Papillary carcinoma  
PCFV                  -       Papillary carcinoma – follicular variant 
FC                       -       Follicular carcinoma 
H&E                    -       Hematoxylin and eosin 
IHC                      -      Immunohistochemistry 
 
 
 
 
 
 
 
MASTER CHART 
S.No AGE SEX 
HPE 
NO. 
CLINICAL 
DIAGNOSIS 
LYMPH NODE 
METASTASIS 
HPE 
IHC -BETA CATENIN 
POSITIVE   
 
      
MEMBRANOUS CYTOPLASM NUCLEAR 
1. 18 FEMALE 586/17 MNG NOMETSTASIS 
PAPILLARY CARCINOMA 
CONVENTIONAL TYPE 
3 3 OCCASIONAL 
2. 50 FEMALE 569/17 TN 
NO 
METASTASIS 
PAPILLARY CARCINOMA 
CONVENTIONAL TYPE 
3 3 OCCASIONAL 
3. 37 FEMALE 745/17 NG 
NO 
METASTASIS 
PAPILLARY CARCINOMA 
CONVENTIONAL TYPE 
2 2 OCCASIONAL 
4. 60 FEMALE 378/17 NG 
NO 
METASTASIS 
PAPILLARY CARCINOMA 
CONVENTIONAL TYPE 
2 2 OCCASIONAL 
5. 35 MALE 4096/16 MNG 
NO 
METASTASIS 
PAPILLARY CARCINOMA 
CONVENTIONAL TYPE 
2 2 
 
6. 35 FEMALE 2659/16 MNG 
NO 
METASTASIS 
PAPILLARY CARCINOMA 
CONVENTIONAL TYPE 
2 2 
 
7. 58 FEMALE 3148/16 TN METASTASIS 
PAPILLARY CARCINOMA 
CONVENTIONAL TYPE 
1 3 
 
8. 49 FEMALE 3205/16 NG 
NO 
METASTASIS 
PAPILLARY CARCINOMA 
CONVENTIONAL TYPE 
2 3 
 
9. 38 FEMALE 75/17 NG 
NO 
METASTASIS 
PAPILLARY CARCCINOMA 
CONVENTIONAL TYPE 
2 2 OCCASIONAL 
10. 16 FEMALE 210/16 MNG 
NO 
METASTASIS 
PAPILLARY CARCINOMA 
CONVENTIONAL TYPE 
2 2 
 
11. 31 FEMALE 2188/17 TN METASTASIS 
PAPILLARY CARCINOMA 
CONVENTIONAL TYPE 
1 3 
 
12. 60 FEMALE 2837/17 TN METASTASIS 
PAPILLARY CARCINOMA 
CONVENTIONAL TYPE 
1 3 
 
13. 68 MALE 2896/17 TN METASTASIS 
PAPILLARY CARCINOMA 
CRIBRIFORM MORULA VARIANT 
1 3 OCCASIONAL 
14. 60 FEMALE 885/16 MNG METASTASIS 
PAPILLARY CARCINOMA 
FOLLICULAR VARIANT 
1 3 
 
15. 65 FEMALE 890/16 TN METASTASIS 
PAPILLARY CARCINOMA 
CRIBRIFORM MORULA VARIANT 
1 3 OCCASIONAL 
16. 26 FEMALE 3039/16 MNG METASTASIS 
PAPILLARY CARCINOMA 
FOLLICULAR VARIANT 
1 3 OCCASIONAL 
17. 62 FEMALE 1403/16 TN METASTASIS 
PAPILLARY CARCINOMA 
CONVENTIONAL TYPE 
2 3 
 
18. 21 FEMALE 2235/17 NG METASTASIS 
PAPILLARY CARCINOMA 
CONVENTIONAL TYPE 
2 3 
 
19. 35 FEMALE 265/17 NG 
NO 
METASTASIS 
PAPILLARY CARCINOMA 
CONVENTIONAL TYPE 
3 2 OCCASIONAL 
20. 37 MALE 3937/17 MNG METASTASIS 
PAPILLARY CARCINOMA HOBNAIL 
VARIANT 
1 3 OCCASIONAL 
21. 38 FEMALE 465/17 MNG METASTASIS 
PAPILLARY CARCINOMA 
FOLLICULAR VARIANT 
1 3 OCCASIONAL 
22. 31 FEMALE E476/17 MNG 
NO 
METASTASIS 
PAPILLARY CARCINOMA 
CONVENTIONAL TYPE 
2 1 
 
23. 37 MALE 3059/16 NG 
NO 
METASTASIS 
FOLLICULAR CARCINOMA 
MINIMALLY INVASIVE 
2 2 
 
24. 65 FEMALE 2437/16 TN METASTASIS 
FOLLICULAR CARCINOMA 
WIDELY INVASIVE 
1 2 
 
25. 32 FEMALE 2761/16 NG 
NO 
METASTASIS 
FOLLICULAR CARCINOMA 
MINIMALLY INVASIVE 
2 1 
 
26. 57 FEMALE 166/16 TN METASTASIS 
FOLLICULAR CARCINOMA 
WIDELY INVASIVE 
1 2 
 
27. 60 MALE 2752/17 TN METASTASIS 
MEDULLARY CARCINOMA OF 
THYROID 
0 0 
 
28. 20 MALE 3923/16 TN METASTASIS 
MEDULLARY CARCINOMA OF 
THYROID 
0 0 
 
29. 39 FEMALE 1421/16 TN METASTASIS 
MEDULLARY CARCINOMA OF 
THYROID 
0 0 
 
30. 56 FEMALE 165/16 TN METASTASIS 
POORLY DIFFERENTIATED 
CARCINOMA 
1 3 
 
